<DOC>
	<DOCNO>NCT00004004</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness procarbazine treat patient progressive recurrent astrocytoma , oligodendroglioma , glioblastoma multiforme follow treatment radiation therapy .</brief_summary>
	<brief_title>Procarbazine Treating Patients With Recurrent Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oral procarbazine administer patient recurrent glioma receive receive anticonvulsant metabolize P450 hepatic enzyme complex . - Determine pharmacokinetics oral procarbazine , include effect hepatic enzyme induce drug , patient . - Assess response rate procarbazine patient . - Evaluate regimen term overall survival duration disease free survival patient . - Evaluate toxicity regimen patient . OUTLINE : Phase I study dose escalation study . Patients stratify accord concurrent use anticonvulsant drug induce cytochrome P450 ( yes v drug modest-induction drug ) . - Phase I : Patients receive oral procarbazine daily 5 day . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos oral procarbazine maximum tolerate dose ( MTD ) determine . - Phase II : Once MTD determine , patient receive procarbazine Phase I . Patients follow every 2 month death . PROJECTED ACCRUAL : A total 24-35 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant glioma one follow type : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Progressive recurrent disease radiotherapy without chemotherapy Measurable disease serial MR CT PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 2 month Hematopoietic : Absolute neutrophil count least 1500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGPT/SGOT great 4 time upper limit normal Renal : Creatinine great 1.7 mg/dL Other : No serious concurrent infection No illness would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year except curatively treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) first course Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen At least 3 week since prior chemotherapy ( least 6 week since prior nitrosoureas ) No 2 prior course carmustine lomustine great 460 mg/m2 220 mg/m2 , respectively No prior procarbazine Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy Surgery : Prior surgery allow Other : Recovered toxicity prior therapy At least 10 day since prior anticonvulsant patient Arm II No concurrent investigational agent No concurrent ethanol , ephedrine , isoproterenol , epinephrine , tricyclic antidepressant , paragyliline , narcotic analgesic , antihistamine , phenothiazine , hypotensive , barbiturate At least 14 day since prior antidepressant ( e.g. , SSRI and/or MAO inhibitor ) Must avoid food high tyramine ( i.e. , dark beer , wine , yogurt , cheese , banana )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>